ERBB2 and breast carcinoma: HER2-positive breast cancer is known to have a higher incidence of BM compared with other subtypes.23) For cases of BM, the efficacy of drugs such as tucatinib and trastuzumab deruxtecan has been suggested, and recent advancements in systemic therapy have significantly improved clinical outcomes.7,24)